Merck

A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies.

Protein expression and purification (2020-04-26)
Gaili Guo, Jinyu Han, Ying Wang, Yifeng Li
RESUMEN

WuXiBody is a novel bispecific antibody (bsAb) platform developed by WuXi Biologics. It enables almost any monoclonal antibody (mAb) sequence pair to be assembled into a bispecific construct. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. WuXiBody's unique design not only ensures desired chain pairing but also facilitates removal of potential product-related impurities. In this work, demonstrated with four WuXiBody-based bsAbs (two asymmetric and two symmetric ones), we showed that Protein A followed by anion exchange (AEX) and mixed-mode chromatography (i.e., Capto MMC ImpRes or Capto adhere ImpRes) can be a potential platform approach for WuXiBody purification.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Millipore
Filtro de profundidad Millistak+® en formato μPOD, A1HC, cellulose fiber, filtration area 0.0023 m2, hydrophilic